Nasal IgA was reported to correlate with protection against influenza virus infection in human cohorts (33), especially for nasal delivered vaccines such as LAIV; therefore, we also measured the anamnestic stalk-specific mucosal IgA antibody titers in nasal washes on day 3 post-pH1N1 (Cal/09) influenza virus challenge infection. This evidence concerns the gene CD79A and infection.